Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, direct delivery of AAV to the CNS was well tolerated in animal models [185, 186].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 5×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
InfluentialSelf-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Lentiviral vector–mediated transduction of autologous CD34+ HSCs has shown therapeutic efficacy in adrenoleukodystrophy (12), and Authorship note: Virginia Haurigot and Sara Marcó contributed equally to this work.”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 12×
“Asymmetrical distribution of AAV-neutralizing antibodies across the BBB .”
InfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Alternatively, AAV9, a serotype recently isolated from human tissue (25), has been shown to have broad tropism and to cross the BBB after systemic administration (26, 27), reverting the neurological phenotype of MPS IIIB (28) and MPS IIIA (29) mice.”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 4×
“…serum NAb titers greater than 1:1,000) and given that only a small proportion of humans will present with very high anti-AAV9 antibody titers (41), GFP expression was detected throughout the CNS, particularly in the leptome-ninges in both injected animals (Figure 11, A and B), though at what…”
InfluentialTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 2×
“In vivo gene therapy offers the possibility of a one-time treat-ment for MPS IIIA and other inherited diseases, with the prospect of lifelong beneficial effects (14).”
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
Self-citationInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610 · cited 1×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511 · cited 4×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Influential
Research works printed but not linked: 1
- Hemsley, 2009, Int J Clin Pharmacol Ther., 47, S118
Cited by
Items 201–223 of 223
Targeted Drug Delivery to the CNS: Beyond the Intrathecal Space
Abrams, D. J., & Stewart, G. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_24
Preclinical Evaluation of Neuraxial Drugs for Safety
Yaksh, T. L., Boyd, R. B., & Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_12
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602150
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602144
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602129
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602156
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602153
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602141
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602135
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602126
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602147
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602138
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602132
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602120
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26602123
Lee, M. H., Kang, S., Um, K.-H., Lee, S. W., Hwang, H., Baek, K., & Choi, J. W. (2024) · Figshare · doi:10.6084/m9.figshare.24995558
AAV-mediated expression of Secreted Klotho as a therapeutic strategy for Alzheimer's disease
Blanch, R. (2023) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) · Cited by 2
Sánchez, A. R., & Molecular, U. A. D. B. D. D. B. I. D. B. (2014) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Gene transfer in the Sandhoff murine model using a specific recombinant AAV9 vector
Niemir, N. (2013) · theses.fr (ABES) · doi:10.70675/f7f92feaz2c9az4447za2f6zb20e4ab539c5
Gene therapy approach on Charcot-Marie-Tooth type 1A rats
Hajjar, H. (2018) · theses.fr (ABES) · doi:10.70675/014f2329za7dbz40a5z9c75z92e60af2b4a0 · Cited by 1
Beard, H., Dayan, S., Barthelson, K., Hewson, L. J., O’Keefe, L. V., & Hemsley, K. M. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70195 · Cited by 2
Metadata
- Authors
- Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-07-01
- Volume
- 123
- Issue
- 8
- Pages
- 3254-3271
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3726158
- OpenAlex
- W2085717798
- Cited by
- 215
- References
- 69
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 27 · 2023: 9 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 13 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 17 · 2014: 28 · 2013: 5
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- Fundación Ramón Areces
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- MPS España
- Universitat Autònoma de Barcelona
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis type IIIA, lysosomal storage disease, AAV9, blood-brain barrier, heparan sulfate, glycosaminoglycan accumulation, intracerebroventricular administration, beagle dogs, mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.